Clinical Trial Update: Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

BeiGene's tislelizumab was evaluated in a Phase 2 trial in patients with resectable esophageal squamous cell carcinoma; the study has completed enrollment and r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Resectable Esophageal Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-12-01